Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

• Prif Awduron: Philip Lee (Awdur), Kristin D. Kistler (Awdur), Luc Douyon (Awdur), Raisa Volodarsky (Awdur), Alex Young (Awdur), Sudeep Karve (Awdur), Swetha Challagulla (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Adis, Springer Healthcare, 2022-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Background and Objective Ibrutinib, an oral Bruton's tyrosine kinase inhibitor, has demonstrated efficacy as a first-line treatment for chronic lymphocytic leukemia in multiple, phase III, randomized clinical trials. This systematic literature review assessed the clinical effectiveness...